carbamates has been researched along with Flatus in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Brecanavir (BCV, 640385) is a novel, potent protease inhibitor (PI) with low nanomolar 50% inhibitory concentrations against PI-resistant human immunodeficiency virus (HIV) in vitro." | 2.72 | Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ( Anderson, MT; Fernandez, P; Ford, SL; Johnson, MA; Murray, SC; Reddy, YS; Stein, DS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ford, SL | 1 |
| Reddy, YS | 1 |
| Anderson, MT | 1 |
| Murray, SC | 1 |
| Fernandez, P | 1 |
| Stein, DS | 1 |
| Johnson, MA | 1 |
1 trial available for carbamates and Flatus
| Article | Year |
|---|---|
Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Topics: Administration, Oral; Adult; Area Under Curve; Benzodioxoles; Capsules; Carbamates; Diarrhea; Dose-R | 2006 |